DaVita Inc.

DVA · NYSE · USD

Can DaVita's clinical work on mortality return treatment volume to growth fast enough to offset a falling commercial mix and government rates that trail its costs?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Sustained mortality improvement

    The bull case is that DaVita's gains in keeping dialysis patients alive are clinical and repeatable, so each year adds treatments rather than merely slowing losses.

  • Value-based care profitability

    Value-based kidney care has crossed into profit, giving DaVita a second earnings stream that grows without adding dialysis chairs.

  • Share count reduction

    Strong free cash flow funds steady buybacks, so per-share profit can rise faster than the operating profit the business generates.

  • Rival clinic closures

    The U.S. market is essentially two large chains, and closures at the rival chain hand DaVita patients it can serve from centers it already operates.

Bear case

  • Treatment growth below target

    The bear case is that treatment growth stays below the company's own target for years while payers shift toward plans that reimburse less.

  • Commercial mix erosion

    Expiring insurance subsidies push patients into lower-paying coverage, and government-set dialysis rates rise slower than the wages and supplies the company buys.

  • Technology spending growth

    Spending on systems and data work is growing faster than revenue, so higher patient volume produces less additional profit than it used to.

  • Flat new patient starts

    New patients starting dialysis are flat, so volume growth depends on patients living longer rather than on a growing population with kidney failure.

Bull and bear points

Growth & Execution

In short: Volume growth has turned positive, but a full recovery to management's long-term target is still years away.

Bull · 2

  • Volume guidance moved from flat to positive growth

    Six months ago management projected flat treatment volume for 2026; the raised range means clinical gains are now showing up in revenue, not only in outcomes.

    Tone shiftQ4 FY2025 → Q1 FY2026

  • Mortality improvement is holding across multiple quarters

    Management says the gain is no longer a single-quarter flu effect, which matters because patients living longer is the main lever on treatment volume.

    Q2 FY2026 call
Bear · 2

  • Return to 2% volume growth is not expected before 2029

    Management expects the clinical initiatives to start helping in about two years and to reach full effect only around 2029, leaving a long stretch of low growth.

    Q4 FY2025 call

  • Expanded HD carries no meaningful financial benefit until 2028

    Management says the new dialyzers do not change results until mortality improves, so the rollout adds training and supply work before it adds profit.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Free cash flow is strong and buybacks cut the share count, while overhead spending outgrows revenue.

Bull · 2

  • Value-based care swung from breakeven goal to profitable

    After aiming only for flat results, IKC now posts a profit and is guided to add operating income each year, giving DaVita earnings that do not depend on treatment volume.

    Tone shiftQ3 FY2025 → Q4 FY2025

  • Buybacks have cut the diluted share count by a fifth

    Diluted shares fell 20.8% between fiscal 2022 and fiscal 2025, so per-share profit rises faster than total profit and cushions slow operating growth.

    Filed financials
Bear · 2

  • Overhead costs are growing faster than revenue

    Gross margin slipped to 32.7% while technology and labor spending rose, so each extra treatment converts into less profit than it did a year ago.

    Filed financials

  • Debt-funded buybacks leave net debt at $10.1 billion

    Net debt rose from $9.5 billion a year earlier, and the 10-K notes repurchases may be financed with more borrowing, which adds interest cost tied to floating rates.

    10-K, filed 2026-02-11

Market Position

In short: DaVita and Fresenius dominate U.S. dialysis, but government rates and expiring subsidies weigh on pricing.

Bull · 1

  • Medicare Advantage raises ESRD rates 6% in 2027

    A dedicated rate increase for kidney failure patients after a period of underfunding makes them more attractive to Medicare Advantage plans, supporting enrollment and payment rates.

    Q4 FY2025 call
Bear · 2

  • Expiring exchange subsidies cut commercial mix

    Management first said the exchange enrollment hit was trending better than its estimate; it later reported mix falling as guided and a larger hit next year.

    Tone shiftQ1 FY2026 → Q2 FY2026

  • 2027 Medicare dialysis rate trails industry cost growth

    The proposed payment update sets the price for most of DaVita's treatments below rising wages and supply costs, squeezing margins unless the final rule improves.

    Q2 FY2026 call